These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38071792)

  • 21. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
    Kreuz S; Holmes KB; Tooze RM; Lefevre PF
    Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer.
    Torres-Ayuso P; Katerji M; Mehlich D; Lookingbill SA; Sabbasani VR; Liou H; Casillas AL; Chauhan SS; Serwa R; Rubin MR; Marusiak AA; Swenson RE; Warfel NA; Brognard J
    Cell Chem Biol; 2024 Feb; 31(2):326-337.e11. PubMed ID: 38016478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy.
    Panchal NK; Sabina EP
    Life Sci; 2020 Aug; 255():117866. PubMed ID: 32479955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and function of PIM kinases in osteosarcoma.
    Mou S; Wang G; Ding D; Yu D; Pei Y; Teng S; Fu Q
    Int J Oncol; 2016 Nov; 49(5):2116-2126. PubMed ID: 27826617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of PIM1/PIM2 kinases in tumors of the male reproductive system.
    Jiménez-García MP; Lucena-Cacace A; Robles-Frías MJ; Narlik-Grassow M; Blanco-Aparicio C; Carnero A
    Sci Rep; 2016 Nov; 6():38079. PubMed ID: 27901106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
    Morishita D; Katayama R; Sekimizu K; Tsuruo T; Fujita N
    Cancer Res; 2008 Jul; 68(13):5076-85. PubMed ID: 18593906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles.
    Chen L; Mao W; Ren C; Li J; Zhang J
    J Med Chem; 2024 Jan; 67(1):38-64. PubMed ID: 38164076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIM kinase (and Akt) biology and signaling in tumors.
    Warfel NA; Kraft AS
    Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the Pim kinases in multiple myeloma.
    Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
    Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice.
    An N; Kraft AS; Kang Y
    J Hematol Oncol; 2013 Jan; 6():12. PubMed ID: 23360755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
    Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
    J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine-Benzoimidazole Structure.
    Sawaguchi Y; Yamazaki R; Nishiyama Y; Sasai T; Mae M; Abe A; Yaegashi T; Nishiyama H; Matsuzaki T
    Anticancer Res; 2017 Aug; 37(8):4051-4057. PubMed ID: 28739687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
    Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
    Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.
    Isaac M; Siu A; Jongstra J
    Drug Resist Updat; 2011; 14(4-5):203-11. PubMed ID: 21601509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based design of low-nanomolar PIM kinase inhibitors.
    Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
    Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.
    Julson JR; Quinn CH; Nazam N; Bownes LV; Stewart JE; Beierle EA
    J Pediatr Surg; 2024 Jul; 59(7):1334-1341. PubMed ID: 38570263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
    Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
    Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
    Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.